Navigation Links
Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Date:4/14/2008

Nonclinical Studies Demonstrate that SNS-595 Acts through a Dual Mechanism

and May Evade Common Drug Resistance Mechanisms

Research Supports Current Clinical Development of SNS-595 in AML and

Ovarian Cancer and Potential in Additional Indications

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented nonclinical data on SNS-595's unique mechanism of action and its anticancer activity at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 in combination with cytarabine in relapsed/refractory acute myeloid leukemia (AML) are both ongoing.

"Data presented today provide important new insights into SNS-595's mechanism as a site-selective DNA intercalator and topoisomerase poison with selectivity for proliferating cells. Through its unique chemical structure and molecular mechanism, SNS-595 avoids common drug resistance pathways and may have advantages over other topoisomerase poisons," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer. "Taken together, these data support our ongoing clinical trials of SNS-595 in platinum-resistant ovarian cancer and acute myeloid leukemia, and provide compelling evidence for future studies of SNS-595 in indications such as breast cancer where topoisomerase II poisons are active."

Sunesis researchers conducted in vitro and cell-based studies elucidating SNS-595's mechanism of action. SNS-595 selectively intercalates DNA and poisons topoisomerase II, resulting in replication-dependent DNA damage, irreversi
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
2. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
6. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
7. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... as evolutionary changes in a living organismhad been thought ... genome. , However, recent studies have shown that cancer ... arise simultaneously and in close proximity to each other. ... regions where chromosomal rearrangements take place. , The discovery, ... one day lead to new cancer therapies, according to ...
(Date:7/30/2014)... News) -- Some obese people have a genetic mutation ... their brains when they see food, researchers report. ... feelings of pleasure and gratification at the sight of ... to prevent overeating, the scientists suggested. More than ... typically caused by a combination of overeating, a lack ...
(Date:7/30/2014)... Georgia (PRWEB) July 30, 2014 The ... and Technology Alliance of TAG (B&TA), today issued its ... TAG Excalibur Awards. , Interested companies have until August ... after which, Semi-Finalists will be selected by the Excalibur ... required to meet with the judges for interviewing process. ...
(Date:7/30/2014)... 30, 2014 The American Telemedicine ... Sens. Thad Cochran (R-MS) and Roger Wicker (R-MS) ... telemedicine coverage under Medicare, Medicaid and Federal Communications ... Mississippi Republicans, introduced the Telehealth Enhancement Act as ... version, H.R. 3306, introduced by Rep. Gregg Harper ...
(Date:7/30/2014)... 2014 2014 Deep Research ... is a professional and in-depth research report ... provides basic Chitosan information, including Chitosan definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4
... 14 ECRI Institute Patient Safety Organization (PSO) ... Coalition for Quality & Patient Safety (CQPS) of ... reporting, and analysis. The Chicagoland PSO focuses on ... specific to Chicago and the surrounding counties. CQPS ...
... 14 May 2009 Research4Life today announces that ... (OARE) program has registered 1500 institutions since its ... percent. This means that scientists, researchers and environmental ... poorest countries can gain free or low cost ...
... Anpath Group, Inc. (OTC Bulleting Board: ANPG), ... (ESI) and its distributor partner, Minntech Japan Corporation, ... 36th annual meeting of the Japanese Society of ... meeting was attended by over 4,000 medical professionals. ...
... Research Month activities include spring dedication at the ... Today Intergraph(R) and the Huntsville Botanical Garden once ... at the Intergraph Garden of Hope spring dedication. ... from the Huntsville community convened to celebrate life ...
... Stem for Life FoundationNEW YORK, May 14 NeoStem, Inc. ... pre-disease collection, processing and long-term storage of adult stem cells ... agreement for Ceres Living, Inc., a developer and direct marketer ... of an innovative nutritional supplement - AIO Premium Cellular Health. ...
... GABLES, Fla., May 14 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: ... first quarter ended March 31, 2009. First Quarter ... the Company reported a net loss of $3,031,201, or $0.22 ... of $1,584,047, or $0.13 per basic and diluted share, for ...
Cached Medicine News:Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 2Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 3Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 4Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 5Health News:Access to environmental research in developing nations grown to 1,500 institutions 2Health News:Anpath Group, Inc. Distributor Introduces Products at the Japanese Society of Intensive Care Medicine Annual Meeting 2Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 2Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 3Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 4Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 5Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 6Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 7Health News:NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions 2Health News:NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions 3Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 5
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today announced ... (the generic equivalent of Zyprexa® injection), in Canada.  Olanzapine ... disturbed behaviors in patients with schizophrenia or bipolar I ... injectable drug, InnoPharma has entered into an agreement with ... will make, use, sell, market and distribute Olanzapine ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
Breaking Medicine Technology:Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... New data being presented at the American College ... San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) ... in a statistically significant greater percentage of nights ... disease (GERD), compared to placebo (p<0.001). In addition, ...
... SAN DIEGO, Oct. 26 Volcano Corporation (Nasdaq: VOLC ... products for the diagnosis and treatment of coronary and peripheral ... results for the third quarter and first nine months of ... hold a conference call to discuss its financial results and ...
Cached Medicine Technology:New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD 2New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD 3Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
... The new SureCut M3500 Radial Microtome has ... is marvelous, and a range of functions and ... users. Based on years of experience and ... innovative design the SureCut M3500 Microtome will be ...
Spare fuse set...
Clock oil, 6 grams net...
Honing compound for knife sharpening, 6 grams net...
Medicine Products: